An expert discusses how rilzabrutinib’s covalent reversible binding mechanism provides a favorable safety profile with only manageable grade 1 to 2 toxicities and no cardiovascular or bleeding ...

Classical hematologist Srila Gopal, MD, tackles the unique complexities of treating and researching sickle cell disease and ...

Previous non-experimental studies suggest an association between paracetamol exposure in the first year of life and subsequent asthma and eczema developing in childhood; however, randomised trials are ...

Rilzabrutinib (Wayrilz; Sanofi) may improve immune thrombocytopenia (ITP) outcomes, enable early intervention, and enhance patient quality of life.

Single dose of avigbagene parvec (FLT201) demonstrates sustained clinical benefit and favorable safety up to two years after withdrawal of prior ...

A new clinic in Cortez is offering platelet-rich plasma injections and other regenerative treatments – and says it’s trying ...

The Bassett Healthcare Network has announced a regenerative and non-operative therapy for muscle, joint, and tendon injuries or issues is now being offered at Cobleskill Regional Hospital.

CRYPTICS study met the primary efficacy endpoint measure, 24-hour chest tube drainage (Difference in LS Means was 142.0 mL; 95.576% confidence ...

Post-CAR T infection prophylaxis should follow European Hematology Association/European Society for Blood and Marrow ...

The conversation around anti-aging is shifting. Forget creams that only cover up fine lines and quick fixes that fade – the future is about science-driven regeneration. Today, consumers want more than ...

Background: Randomized controlled trials (RCTs) evaluate short-term efficacy/safety of thrombopoietin receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP), leaving long-term outcomes unclear.